Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hullo! Today, we talk about Amgen’s positive new PCSK9 data, learn more about the new NIH office meant to reduce reliance on animal testing, and more.
Amgen’s Repatha trial shows heart risk reduction
Amgen said yesterday that its cholesterol-lowering injection Repatha cut the risk of a composite of heart disease death, heart attacks, and strokes in a 12,000-patient trial, bolstering hopes for wider use of PCSK9 inhibitors after years of slow adoption, STAT’s Matt Herper writes.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
